Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Cefpodoxime

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Tablet and Chewable Tablet Multiple FDA sponsors Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
Apr 22, 2026, 10:07 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: April 15, 2026

Updated: April 15, 2026, 10:04 AM UTC

Sources:
Image coming soon
Cefpodoxime

Cefpodoxime

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Tablet and Chewable Tablet Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Cefpodoxime

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis . For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , S. aureus , Streptococcus canis (group G, beta-hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis . Species commonly shown: Both, Dog, No Use Class Stated Or Implied.

Generic name
Cefpodoxime
Brand names
Simplicef®, Cefpodoxime Proxetil Tablets
Manufacturer
Multiple FDA sponsors
Species
Both, Dog, No Use Class Stated Or Implied
Dosage forms
Tablet and Chewable Tablet, Tablet
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Simplicef® Cefpodoxime Proxetil Tablets
Dosage forms
Tablet and Chewable Tablet Tablet

Indications / Uses

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis . For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , S. aureus , Streptococcus canis (group G, beta-hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis .

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Side Effects

Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Lethargy (see also Central nervous system depression in Neurological), Seizure NOS.

FAQ

Both, Dog, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Tablet and Chewable Tablet, Tablet

Related Conditions

Abscesses (cat bite abscess)

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , S. aureus , Streptococcus canis (group G, beta-hemolytic), Escherichia coli , Pasteurella mul...

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)
  • Difficulty to rise (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • wobbly/unsteady walking
  • Loss of appetite
  • Difficulty to rise

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
  • Difficulty to rise (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA sponsors
Form: Tablet, Tablet and Chewable Tablet
Identifiers:
ANADA: 200543 ANADA: 200815 NADA: 141232 NDC Package: 11695-7040-1 NDC Package: 11695-7040-2 NDC Package: 11695-7041-1 NDC Package: 11695-7041-2 NDC Package: 17033-431-10 NDC Package: 17033-432-10 NDC Package: 54771-5228-1 NDC Package: 54771-5228-2 NDC Package: 54771-5229-1 NDC Package: 54771-5229-2 NDC Package: 73309-025-01 NDC Package: 73309-025-02 NDC Package: 73309-025-03 NDC Package: 73377-069-01 NDC Package: 73377-069-02 NDC Package: 73377-069-03 NDC Package: 86101-033-71
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
19
Species represented
2
Grouped by Body System
Digestive (3) · Loss of appetite, Diarrhea, Bloody diarrhoea Skin & allergy (2) · Hair loss, Application site hair loss Neurologic (1) · Unsteady walking (ataxia) Behavior (1) · Behavioral disorder (unspecified) Other (25) · Drunken gait, Difficulty to rise, Decreased red blood cell count
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (24) Cat (8)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Digestive Dog Serious - 1
Skin & allergy Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Digestive Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Digestive Dog Non-serious - 1
Behavior Dog Non-serious - 1
Other Cat Non-serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

3

FOI

4

Cefpodoxime Proxetil Tablets

SPL · SPL

Open original
FDA Structured Product Label

Cefpodoxime Proxetil Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Felix Pharmaceuticals Pvt. Ltd.
ANADA
200-815
Status
RX
Form
Tablet
Route
Oral
Composition / specifications
100 mg and 200 mg

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, S. aureus, Streptococcus canis (group G, beta-hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

Dosage

5 to 10 mg per kilogram (2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.

Cefpodoxime Proxetil Tablets

SPL · SPL

Open original
FDA Structured Product Label

Cefpodoxime Proxetil Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Dechra Veterinary Products LLC
ANADA
200-543
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
100 mg, 200 mg

Label highlights

Indication

For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis

Dosage
5-10 mg/kg (2.3-4.5 mg/lb) body weight once a day for 5-7 days or 2-3 days beyond the cessation of clinical signs, up to a maximum of 28 days. Treatment of acute infections should not be continued for more than 3-4 days if no response to therapy is seen
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian

Simplicef®

SPL · SPL

Open original
FDA Structured Product Label

Simplicef®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-232
Status
RX
Form
Tablet and Chewable Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

Dosage

5 to 10 milligram per kilogram (2.3 to 4.5 milligram per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.

Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FOI Summary oA 200-815 Approved July 8, 2025.pdf

FOI · FOI

Open original

UCM338192.pdf

FOI · FOI

Open original

UCM433791.pdf

FOI · FOI

Open original

ucm118043.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Tablet, Tablet and Chewable Tablet • Oral
Applications: ANADA 200-815 • ANADA 200-543 • NADA 141-232
Documents: 4 (FOI: 4) • SPL: 3 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 26 • Cat 2 • View
Case summaries: 6 (showing 6) • View
openFDA reports are unverified and do not prove causation.
Explore
Related conditions: Abscesses (cat bite abscess)
Linked using: Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Loss of appetite (1) Difficulty to rise (1) Decreased haematocrit (1) Decreased bowel movements (1) Death by euthanasia (1) Death (1) Deafness (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200543 ANADA: 200815 NADA: 141232 NDC Package: 11695-7040-1 NDC Package: 11695-7040-2 NDC Package: 11695-7041-1 NDC Package: 11695-7041-2 NDC Package: 17033-431-10 NDC Package: 17033-432-10 NDC Package: 54771-5228-1 NDC Package: 54771-5228-2 NDC Package: 54771-5229-1 NDC Package: 54771-5229-2 NDC Package: 73309-025-01 NDC Package: 73309-025-02 NDC Package: 73309-025-03 NDC Package: 73377-069-01 NDC Package: 73377-069-02 NDC Package: 73377-069-03 NDC Package: 86101-033-71 NDC Package: 86101-033-76 NDC Package: 86101-034-71 NDC Package: 86101-034-76 NDC Package: 86136-134-36
Package NDC Product NDC Form / Route Status
11695-7040-1 11695 -
11695-7040-2 11695 -
11695-7041-1 11695 -
11695-7041-2 11695 -
17033-431-10 17033 -
17033-432-10 17033 -
54771-5228-1 54771 -
54771-5228-2 54771 -
54771-5229-1 54771 -
54771-5229-2 54771 -
73309-025-01 73309 -
73309-025-02 73309 -
73309-025-03 73309 -
73377-069-01 73377 -
73377-069-02 73377 -
73377-069-03 73377 -
86101-033-71 86101 -
86101-033-76 86101 -
86101-034-71 86101 -
86101-034-76 86101 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • FOI Summary oA 200-815 Approved July 8, 2025.pdf • FOI summary • Official • July 31, 2025
    FDA FOI summary for application 200815
  • UCM338192.pdf • FOI summary • Official • March 16, 2019
    FDA FOI summary for application 200543
  • ucm118043.pdf • FOI summary • Official • March 15, 2019
    FDA FOI summary for application 141232
  • UCM433791.pdf • FOI summary • Official • March 15, 2019
    FDA FOI summary for application 141232

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 28 Clinical 15 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Clinical, 2026-04-17)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Clinical, 2026-04-16)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Clinical, 2026-04-15)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Clinical, 2026-04-11)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-21)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-20)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-19)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-17)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Letharg… (Clinical, 2026-04-11)
  • usage: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptoc… (Clinical, 2026-04-17)
  • usage: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptoc… (Clinical, 2026-04-16)
  • usage: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptoc… (Clinical, 2026-04-15)
  • usage: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptoc… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-04-22)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-02-12)
  • indications: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus c… (Official, 2026-05-05)
  • indications: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus c… (Official, 2026-05-03)
  • indications: For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus c… (Official, 2026-05-02)
Recent Revisions
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-21 10:07 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-21 10:07 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-21 10:07 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-21 10:07 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-21 10:07 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-21 10:07 by curated_loader • Official FDA application reference for Senvelgo.
  • monitoring updated 2026-04-20 10:08 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-20 10:08 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-20 10:08 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-20 10:08 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-20 10:08 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-20 10:08 by curated_loader • Official FDA application reference for Senvelgo.
  • monitoring updated 2026-04-19 10:08 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-19 10:08 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-19 10:08 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-19 10:08 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-19 10:08 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Cefpodoxime Proxetil Tablets
RX
Cefpodoxime proxetil
Tablet • Oral
Label highlights
Official documents
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-815 Approved Jul 31, 2025
Cefpodoxime Proxetil Tablets
RX
Cefpodoxime proxetil
Tablet • Oral
Label highlights
Official documents
Dechra Veterinary Products LLC ANADA 200-543 Approved Mar 16, 2019
Simplicef®
RX
Cefpodoxime proxetil
Tablet and Chewable Tablet • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-232 Approved Mar 15, 2019

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
100 mg and 200 mg
Dogs
Indication

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, S. aureus, Streptococcus canis (group G, beta-hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

Dosage

5 to 10 mg per kilogram (2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
100 mg, 200 mg
Label highlights
Indication

For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis

Dosage
5-10 mg/kg (2.3-4.5 mg/lb) body weight once a day for 5-7 days or 2-3 days beyond the cessation of clinical signs, up to a maximum of 28 days. Treatment of acute infections should not be continued for more than 3-4 days if no response to therapy is seen
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Dogs
Indication

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius, Staphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

Dosage

5 to 10 milligram per kilogram (2.3 to 4.5 milligram per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.

Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis . For the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus intermedius , Staphylococcus aureus , Streptococcus canis (group G, ß hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of Staphylococcus pseudintermedius , S. aureus , Streptococcus canis (group G, beta-hemolytic), Escherichia coli , Pasteurella multocida , and Proteus mirabilis .

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Dog Diarrhea (1) • Cat Bloody diarrhoea (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Hair loss (1) • Dog Application site hair loss (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Dog

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Dog

Showing top 5 for Behavior.

Other
Drunken gait (1) • Dog Difficulty to rise (1) • Dog Decreased red blood cell count (1) • Dog Decreased haematocrit (1) • Dog Decreased bowel movements (1) • Cat
Show more (20)
Death by euthanasia (1) • Dog Death (1) • Dog Deafness (1) • Dog Crystalluria (1) • Dog Cough (1) • Dog Corneal oedema (1) • Dog Conjunctivitis (1) • Dog Conjunctival oedema (1) • Dog Cognitive disorder NOS (1) • Dog Cellulitis (1) • Dog Bumps on skin (1) • Dog Balance impaired (1) • Cat Bacterial skin infection NOS (1) • Dog Arthropathy NOS (1) • Cat Application site scab (1) • Cat Application site irritation (1) • Cat Application site discharge NOS (1) • Dog Alkaline urine (1) • Dog Abnormal radiograph finding (1) • Cat Abnormal histology NOS (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Retriever - Golden', 'Poodle (unspecified)'], Female, 12 year, 43.273 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 dose per animal, Frequency: 1 per day • Reactions: Urinary tract infection, Medication error NOS, Lack of efficacy - NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074070
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 12.00 Year
  • Weight: 43.273 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 1 dose per animal
  • Frequency: 1 per day
Reactions Reported:
Urinary tract infection Medication error NOS Lack of efficacy - NOS
Outcomes: Ongoing

Cat, Cat (other), Male, 16 year, 3.969 kilogram • Drug: MSK, Tablet, Oral, Dose: 200 Milligram per animal, Frequency: 12 per hour • Reactions: Neutropenia, Medication error NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074220
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 16.00 Year
  • Weight: 3.969 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 200 Milligram per animal
  • Frequency: 12 per hour
Reactions Reported:
Neutropenia Medication error NOS
Outcomes: Ongoing

Dog, Retriever - Labrador, Female, 4 year, 57.5 kilogram • Drug: MSK, Tablet, Oral, Dose: 300 Milligram per animal, Frequency: 24 per hour • Reactions: Vomiting • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-075022
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 4.00 Year
  • Weight: 57.500 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 300 Milligram per animal
  • Frequency: 24 per hour
Reactions Reported:
Vomiting
Outcomes: Recovered/Normal

Dog, ['Chihuahua', 'Dog (unknown)'], Female, 20 week, 2.26 kilogram • Drug: MSK, Unknown • Reactions: Icterus, Death, Other abnormal test result NOS, Elevated liver enzymes NOS, Swollen joint… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-074897
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 20.00 Week
  • Weight: 2.260 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Icterus Death Other abnormal test result NOS Elevated liver enzymes NOS Swollen joint Localised hair loss Skin lesion NOS Conjunctival oedema Corneal oedema Skin scab Swollen limb Tiredness (lethargy) Loss of appetite Ear infection NOS Local swelling
Outcomes: Died

Dog, Corgi (unspecified), Male, 11 week, 3.175 kilogram • Drug: MSK, Tablet, Oral, Dose: 200 Milligram per animal • Reactions: Decreased haematocrit, Crystalluria, Proteinuria, Hypoproteinaemia, Overdose… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-073099
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Week
  • Weight: 3.175 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 200 Milligram per animal
Reactions Reported:
Decreased haematocrit Crystalluria Proteinuria Hypoproteinaemia Overdose Alkaline urine
Outcomes: Ongoing

Dog, ['Plott', 'Dog (unknown)'], Male, 9 year, 22.27 kilogram • Drug: MSK, Tablet, Oral, Dose: 150 Milligram per animal, Frequency: 24 per hour • Reactions: Vomiting, Facial swelling (possible allergy) • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-072799
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 9.00 Year
  • Weight: 22.270 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 150 Milligram per animal
  • Frequency: 24 per hour
Reactions Reported:
Vomiting Facial swelling (possible allergy)
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.